Domains targeting keyword arrhythmias

Learn about AMRIX® (Cyclobenzaprine Hydrochloride Extended‐Release Capsules) for the treatment of muscle spasm due to acute, painful musculoskeletal conditions. AMRIX is a prescription medicine used along with rest and physical therapy to help treat muscle spasm due to acute, painful musculoskeletal problems. AMRIX should only be used for up to 2 or 3 weeks. It is not known if AMRIX is effective when used for longer periods. It is not known if AMRIX is safe and effective in children. Do not take AMRIX if you: • are allergic to cyclobenzaprine or any of the components of AMRIX. Talk to your healthcare provider or get medical help right away if you have symptoms of an allergic reaction such as difficulty breathing, hives, swelling of your face or tongue, or itching • are taking certain antidepressants known as monoamine oxidase (MAO) inhibitors, or it has been 14 days or less since you stopped taking a MAO inhibitor. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure • have had a recent heart attack • have heart rhythm problems (arrhythmias) • have heart failure • have an overactive thyroid (hyperthyroidism). Talk to your healthcare provider before taking this medicine if you have any of the conditions listed above. You should not drink alcohol until you know how AMRIX affects you. Taking AMRIX with alcohol or other medicines that depress your central nervous system can slow your thinking and physical response times. Do not drive, operate machinery, or do other dangerous activities until you know how AMRIX affects you. AMRIX may cause serious side effects that may lead to heart attack or stroke. Call your healthcare provider immediately or go to the nearest hospital emergency room if you have: • irregular or abnormal heartbeats (arrhythmias) • fast heartbeat (tachycardia). Serotonin syndrome is a serious medical condition that may happen when AMRIX is taken with certain other medicines. Call your healthcare provider right away or go to the nearest hospital emergency room if you become severely ill and have some or all of these symptoms: • agitation, hallucinations, coma, or other changes in mental status • coordination problems or muscle twitching (overactive reflexes) • fast heartbeat, high or low blood pressure • sweating or fever • nausea, vomiting, or diarrhea • muscle stiffness or tightness. The most common side effects of AMRIX include dry mouth, dizziness, fatigue, constipation, nausea, upset stomach, and drowsiness. Tell your healthcare provider if you get any side effect that bothers you or that does not go away. These are not all the possible side effects of AMRIX. For more information, talk to your healthcare provider or pharmacist. Please see the Patient Information Leaflet within the accompanying Full Prescribing Information.

Francisco Leyva, Consultant Cardiologist in Birmingham, provides information for patients with cardiac conditions, including heart attacks, high blood pressure, arrhythmias, heart failure and cardiac resynchronisation therapy.

3D realistic mathematical modeling of cardiac dynamics and arrhythmias in anatomically correct hearts

The group provides an international level of expertise in the invasive management of heart rhythm problems includes complex pacemaker or defibrillator implantation in patients at risk of heart-rhythm related collapse, and catheter ablation for management.

Learn more about single-bolus TNKase® (tenecteplase) acute myocardial infarction treatment and the 5-second TNKase® dosing and administration. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.

Emergency cardiac care, cardiology, EKGs, ECGs, electrocardiography, echocardiography, dysrhythmias, arrhythmias, STEMI, NonSTEMI, NSTEMI, cardiology

Emergency cardiac care, cardiology, EKGs, ECGs, electrocardiography, echocardiography, dysrhythmias, arrhythmias, STEMI, NonSTEMI, NSTEMI, cardiology

Find information for healthcare professionals about Rituxan® (rituximab), the only FDA-approved treatment proven to induce remission in patients with GPA and MPA. INDICATION STATEMENT - Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Limitations of Use: Rituxan is not recommended for use in patients with severe, active infections BOXED WARNINGS and Additional Important Safety Information BOXED WARNINGS Infusion Reactions: Rituxan administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML): PML, including fatal PML, can occur in patients receiving Rituxan. Warnings and Precautions Rituxan administration can also result in additional serious, including fatal, adverse reactions including: - Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti‑hyperuricemic agents, monitor renal function - Infections: Withhold Rituxan and institute appropriate anti-infective therapy - Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events - Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms - Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan - Cytopenias: Monitor blood counts at regular intervals Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with Rituxan. Observe patients with GPA and MPA closely for signs of infection if immunosuppressants other than corticosteroids are used concomitantly - The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA - Common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see the Rituxan full prescribing information, including BOXED WARNINGS.

Home. Discussion, debate, diversity, innovation and review - HRC, the word in education in arrhythmias.

Emergency cardiac care, cardiology, EKGs, ECGs, electrocardiography, echocardiography, dysrhythmias, arrhythmias, STEMI, NonSTEMI, NSTEMI, cardiology

Peer-rewieved medical journal

Interactive multimedia tutorials and tests are available for aortic and mitral valve disease, and for supraventricular tachycardias (SVTs), using actual patient sounds, video, and custom animations.

Quantifying Vital Signals. Accurately. See how our innovative technology can assist with ECG noise filtering, heart rate measurement, arrhythmia detection, interval measurement, and cardiac safety screening.

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities.

ANSWatch wrist monitor is developed by Sun Scientific for measurement of heart rate variability (HRV, related to autonomic nervous system), irregular heartbeats (arrhythmias), heart rate, and blood pressure. It also includes pulse waveform diagnosis tools.

InfoBionic empowers physicians with the control they need to transform the efficiency with which they diagnose and monitor patients with cardiac arrhythmias.

State-of-the art treatment for cardiac arrhythmias and complex ablations including atrial fibrillation and ventricular tachycardia in the DC region

Interactive multimedia tutorials and tests are available for aortic and mitral valve disease, and for supraventricular tachycardias (SVTs), using actual patient sounds, video, and custom animations.

Emergency cardiac care, cardiology, EKGs, ECGs, electrocardiography, echocardiography, dysrhythmias, arrhythmias, STEMI, NonSTEMI, NSTEMI, cardiology

The Cardiac Electrophysiology Society (CES) is an international society of basic and clinical scientists and physicians interested in cardiac electrophysiology and arrhythmias.

The Cardiovascular Centre has a highly trained team of Cardiologists who offer a full range of adult and paediatric cardiology services in Adelaide. The centre is well equipped to provide the highest quality of care to patients with on call services that are available 24hrs a day, 7 days a week. Our services are accessible for referring general practitioners and physicians. Our Cardiologists have admitting rights to teaching and private hospitals to ensure rapid response and treatment for cardiac emergencies.

Emergency cardiac care, cardiology, EKGs, ECGs, electrocardiography, echocardiography, dysrhythmias, arrhythmias, STEMI, NonSTEMI, NSTEMI, cardiology

Below you can find an organised list of videos you can find on my channel. Medical Software Tutorials Video Lectures Anatomy videos Gross Anatomy - Dalhousie University BD Chaurasia Anatomy Videos Medical School Pathology - Dr. Minarcik Microbiology, Immunology and Parasitology Video Lectures Infectious Diseases [University of South Carolina] Arrhythmias and Pacemaker Basics [Hong Kong…

Home. Working together to improve the diagnosis, treatment and quality of life for all those affected by arrhythmias.

Working together to improve the diagnosis, treatment and quality of life for all those affected by arrhythmias.

Alaska Heart & Vascular Institute is Alaska’s leading provider of cardiovascular care.